4D MOLECULAR THERAPEUTICS, INC. - Annual Financials - Cash Flow (SEC)

Updated on January 3, 2026.

Related Topics: SEC Topic List.

Data Source: SEC.

See details in table below.

You can see similar for other companies.

4D MOLECULAR THERAPEUTICS, INC. - Annual Cash Flow (In Thousands of USD, Except Per Share Amounts)

Breakdown	2024-12-31	2023-12-31	2022-12-31
Net loss	-160868	-100837
Stock-based compensation expense	26116	19665
Vesting of common stock warrants in return for services	66	88
Change in fair value of derivative liability	41	157
Depreciation and amortization	4653	4204
Amortization of right-of-use assets	2052	1545
Net amortization (accretion) of premium (discount) on marketable securities	7182	1244
Prepaid expenses and other current assets	1699	1399
Other assets	3577	70
Accounts payable	871	896
Accrued and other liabilities	6524	3371
Deferred revenue	69	-715
Operating lease liabilities	-1651	-1453
Net cash used in operating activities	-134585	-75792
Acquisition of property and equipment	3786	2771
Purchase of marketable securities	467652	54802
Maturities of marketable securities	169001	173290
Net cash provided by (used in) investing activities	-302437	115717
Issuance of common stock upon public offerings, net of issuance costs	15300	19136
Issuance of common stock upon exercise of stock options and warrants	4580	7310
Issuance of common stock - 2020 ESPP	1258	1178
Net cash provided by financing activities	337250	156832
Net increase (decrease) in cash and cash equivalents	-99772	196757
Cash and cash equivalents, beginning of period	149336	249108	52351
Cash and cash equivalents, end of period	149336	249108	52351
Purchases of property and equipment in accounts payable and accrued and other liabilities	509	234
Right-of-use assets obtained in exchange for lease obligations	11587
Deferred ATM costs reclassification		468